JP2020522568A5 - - Google Patents

Download PDF

Info

Publication number
JP2020522568A5
JP2020522568A5 JP2020516788A JP2020516788A JP2020522568A5 JP 2020522568 A5 JP2020522568 A5 JP 2020522568A5 JP 2020516788 A JP2020516788 A JP 2020516788A JP 2020516788 A JP2020516788 A JP 2020516788A JP 2020522568 A5 JP2020522568 A5 JP 2020522568A5
Authority
JP
Japan
Prior art keywords
capecitabine
day
pharmaceutical composition
administration
day cycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020516788A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020522568A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/035653 external-priority patent/WO2018223029A1/en
Publication of JP2020522568A publication Critical patent/JP2020522568A/ja
Publication of JP2020522568A5 publication Critical patent/JP2020522568A5/ja
Withdrawn legal-status Critical Current

Links

JP2020516788A 2017-06-02 2018-06-01 テセタキセル及びカペシタビンの投与スケジュール Withdrawn JP2020522568A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762514483P 2017-06-02 2017-06-02
US62/514,483 2017-06-02
PCT/US2018/035653 WO2018223029A1 (en) 2017-06-02 2018-06-01 Dosing schedule for tesetaxel and capecitabine

Publications (2)

Publication Number Publication Date
JP2020522568A JP2020522568A (ja) 2020-07-30
JP2020522568A5 true JP2020522568A5 (https=) 2021-07-26

Family

ID=64455637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020516788A Withdrawn JP2020522568A (ja) 2017-06-02 2018-06-01 テセタキセル及びカペシタビンの投与スケジュール

Country Status (14)

Country Link
US (1) US20200179427A1 (https=)
EP (1) EP3630091A4 (https=)
JP (1) JP2020522568A (https=)
KR (1) KR20200014880A (https=)
CN (1) CN111032035A (https=)
AU (1) AU2018275122A1 (https=)
BR (1) BR112019025164A2 (https=)
CA (1) CA3065783A1 (https=)
EA (1) EA201992852A1 (https=)
IL (1) IL270973A (https=)
MA (1) MA50039A (https=)
MX (1) MX2019014489A (https=)
TW (1) TW201902473A (https=)
WO (1) WO2018223029A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53929A (fr) * 2018-10-17 2021-08-25 Odonate Therapeutics Inc Méthodes de traitement de tumeurs du système nerveux central au moyen de tesetaxel
WO2021034335A1 (en) * 2019-08-16 2021-02-25 Odonate Therapeutics, Inc. Methods of administering tesetaxel with glucocorticoids that are cyp3a4 inducers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168451A1 (en) * 2015-04-14 2016-10-20 Merrimack Pharmaceuticals, Inc. Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment

Similar Documents

Publication Publication Date Title
RU2016146129A (ru) Способы лечения раннего рака молочной железы трастузумабом-mcc-dm1 и пертузумабом
JP2016530280A5 (https=)
RU2016112608A (ru) Лечение рака комбинацией плинабулина и таксана
RU2017134443A (ru) Способ лечения с применением традипитанта
RU2017132877A (ru) Комбинация антагониста pd-1 и эрибулина для лечения рака
IL320452A (en) Combination therapy for prostate cancer
RU2015120181A (ru) Чресслизистая доставка токотриенола
JP2019530706A5 (https=)
JP2018522028A5 (https=)
JP2020522568A5 (https=)
JP2017503846A5 (https=)
IL274343B2 (en) Treatment methods and maintenance treatment for bladder cancer using gemcitabine
RU2020120156A (ru) Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена
WO2017142871A8 (en) Methods comprising fixed intermittent dosing of cediranib
CN106924388B8 (zh) 一种治疗失眠的药物组合物及其制备方法、制剂与应用
RU2018131573A (ru) Способ лечения больных раком с тяжелой почечной недостаточностью
RU2015139515A (ru) Комбинированное лечение
RU2019126627A (ru) Схема введения доз комбинации церитиниба и молекулы антитела к pd-1
RU2020108631A (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты
JP2015510945A5 (https=)
FI3302551T3 (fi) Menetelmiä her2-positiivisen, aiemmin hoitamattoman metastaattisen rintasyövän hoitamiseksi
JP2016522826A5 (https=)
RU2015145948A (ru) Противоопухолевый агент, включающий гидрат гидрохлорида иринотекана
JP2016521760A5 (https=)
JP2017530142A5 (https=)